nach oben

Erschienen in:

01.10.2013 | Original Communication

Diagnostic odyssey of patients with myotonic dystrophy

verfasst von: James E. Hilbert, Tetsuo Ashizawa, John W. Day, Elizabeth A. Luebbe, William B. Martens, Michael P. McDermott, Rabi Tawil, Charles A. Thornton, Richard T. Moxley III

Erschienen in: Journal of Neurology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

The onset and symptoms of the myotonic dystrophies are diverse, complicating their diagnoses and limiting a comprehensive approach to their clinical care. This report analyzes the diagnostic delay (time from onset of first symptom to diagnosis) in a large sample of myotonic dystrophy (DM) patients enrolled in the US National Registry [679 DM type 1 (DM1) and 135 DM type 2 (DM2) patients]. Age of onset averaged 34.0 ± 14.1 years in DM2 patients compared to 26.1 ± 13.2 years in DM1 (p < 0.0001). The most common initial symptom in DM2 patients was leg weakness (32.6 %) compared to grip myotonia in DM1 (38.3 %). Pain was reported as the first symptom in 11.1 % of DM2 and 3.0 % of DM1 patients (p < 0.0001). Reaching the correct diagnosis in DM2 took 14 years on average (double the time compared to DM1) and a significantly higher percentage of patients underwent extended workup including electromyography, muscle biopsies, and finally genetic testing. DM patients who were index cases experienced similar diagnostic delays to non-index cases of DM. Further evaluation of how to shorten these diagnostic delays and limit their impact on burdens of disease, family planning, and symptom management is needed.

Nur mit Berechtigung zugänglich

Harper PS (2001) Myotonic dystrophy. W.B Saunders Company, London

Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T, Sohn R, Zemelman B, Snell RG, Rundle SA, Crow S, Davies J, Shelbourne P, Buxton J, Jones C, Juvonen V, Johnson K, Harper PS, Shaw DJ, Housman DE (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 68:799–808PubMedCrossRef

Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P, Wieringa B, Korneluk R, Perryman MB, Epstein HF, Caskey CT (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255:1256–1258PubMedCrossRef

Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barcelo J, O’Hoy K, Leblond S, Earle-MacDonald J, De Jong P, Wieringa B, Korneluk R (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science 255:1253–1255PubMedCrossRef

Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293:864–867PubMedCrossRef

Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW (1998) Genetic mapping of a second myotonic dystrophy locus. Nat Genet 19:196–198PubMedCrossRef

Cho DH, Tapscott SJ (2007) Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 1772:195–204PubMedCrossRef

Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP (2003) Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60:657–664PubMedCrossRef

Osborne RJ, Thornton CA (2006) RNA-dominant diseases. Hum Mol Genet 15 Spec No 2:R162-R169

10.

Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891–905PubMedCrossRef

11.

Douniol M, Jacquette A, Cohen D, Bodeau N, Rachidi L, Angeard N, Cuisset JM, Vallee L, Eymard B, Plaza M, Heron D, Guile JM (2012) Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. Dev Med Child Neurol 54:905–911PubMedCrossRef

12.

Schara U, Schoser BG (2006) Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 13:71–79PubMedCrossRef

13.

Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Otto M, Heine R, Moxley RT (1994) Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness and cataracts. Neurology 44:1448–1452PubMedCrossRef

14.

Thornton CA, Griggs RC, Moxley RT (1994) Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 35:269–272PubMedCrossRef

15.

Meola G, Moxley RT III (2004) Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 251:1173–1182PubMedCrossRef

16.

Udd B, Meola G, Krahe R, Wansink DG, Bassez G, Kress W, Schoser B, Moxley R (2011) Myotonic dystrophy type 2 (DM2) and related disorders Report of the 180th ENMC Workshop including guidelines on diagnostics and management 3–5 December 2010, Naarden, The Netherlands. Neuromuscul Disord 21:443–450PubMedCrossRef

17.

Gaul C, Schmidt T, Windisch G, Wieser T, Muller T, Vielhaber S, Zierz S, Leplow B (2006) Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 67:350–352PubMedCrossRef

18.

Minnerop M, Weber B, Schoene-Bake JC, Roeske S, Mirbach S, Anspach C, Schneider-Gold C, Betz RC, Helmstaedter C, Tittgemeyer M, Klockgether T, Kornblum C (2011) The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain 134:3530–3546PubMedCrossRef

19.

Franc DT, Muetzel RL, Robinson PR, Rodriguez CP, Dalton JC, Naughton CE, Mueller BA, Wozniak JR, Lim KO, Day JW (2012) Cerebral and muscle MRI abnormalities in myotonic dystrophy. Neuromuscul Disord 22:483–491PubMedCrossRef

20.

Kornblum C, Reul J, Kress W, Grothe C, Amanatidis N, Klockgether T, Schroder R (2004) Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2. J Neurol 251:710–714PubMedCrossRef

21.

Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, Cattaneo E, Cotelli M, Gobbo C, Fazio F, Siciliano G, Mancuso M, Vitelli E, Zhang S, Krahe R, Moxley RT (2003) Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord 13:813–821PubMedCrossRef

22.

Sansone V, Gandossini S, Cotelli M, Calabria M, Zanetti O, Meola G (2007) Cognitive impairment in adult myotonic dystrophies: a longitudinal study. Neurol Sci 28:9–15PubMedCrossRef

23.

Hilbert JE, Luebbe EA, Martens WB, Moxley RT III, Registry Scientific Advisory Committee (2009) Diagnostic odyssey of myotonic dystrophy type 2 (DM2) patients, Poster P4–08; 9th international myotonic dystrophy consortium meeting; Wurzburg Germany. Med Gen 21:444

24.

Milone M, Batish SD, Daube JR (2009) Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia. Muscle Nerve 39:383–385PubMedCrossRef

25.

Young NP, Daube JR, Sorenson EJ, Milone M (2010) Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2. Muscle Nerve 41:758–762PubMedCrossRef

26.

Auvinen S, Suominen T, Hannonen P, Bachinski LL, Krahe R, Udd B (2008) Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. Arthritis Rheum 58:3627–3631PubMedCrossRef

27.

Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, Peltonen L, Krahe R, Udd B (2011) Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 19:776–782PubMedCrossRef

28.

Foff EP, Mahadevan MS (2011) Therapeutics development in myotonic dystrophy type 1. Muscle Nerve 44:160–169PubMedCrossRef

29.

Lee JE, Bennett CF, Cooper TA (2012) RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci USA 109:4221–4226PubMed

30.

Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488:111–115PubMedCrossRef

31.

Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, Tawil R, Thornton CA, Moxley RT III (2012) If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials 33:302–311PubMedCrossRef

32.

Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R III (2012) Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79:348–357PubMedCrossRef

33.

Rubinstein YR, Groft SC, Bartek R, Brown K, Christensen RA, Collier E, Farber A, Farmer J, Ferguson JH, Forrest CB, Lockhart NC, McCurdy KR, Moore H, Pollen GB, Richesson R, Miller VR, Hull S, Vaught J (2010) Creating a global rare disease patient registry linked to a rare diseases biorepository database: rare disease-HUB (RD-HUB). Contemp Clin Trials 31:394–404PubMedCrossRef

34.

Thompson R, Schoser B, Monckton DG, Blonsky K, Lochmuller H (2009) Patient Registries and Trial Readiness in Myotonic Dystrophy–TREAT-NMD/Marigold International Workshop Report. Neuromuscul Disord 19:860–866PubMedCrossRef

35.

Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, Mathews KD, Miller TM, Matthews DJ, Miller LA, Cunniff C, Druschel CM, Moxley RT (2009) Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 155:380–385PubMedCrossRef

36.

Schneider C, Ziegler A, Ricker K, Grimm T, Kress W, Reimers CD, Meinck H, Reiners K, Toyka KV (2000) Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q. Neurology 55:383–388PubMedCrossRef

37.

George A, Schneider-Gold C, Zier S, Reiners K, Sommer C (2004) Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 61:1938–1942PubMedCrossRef

38.

Suokas KI, Haanpaa M, Kautiainen H, Udd B, Hietaharju AJ (2012) Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 45:70–74PubMedCrossRef

39.

Gagnon C, Chouinard MC, Laberge L, Veillette S, Begin P, Breton R, Jean S, Brisson D, Gaudet D, Mathieu J (2010) Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscul Disord 20:847–851PubMedCrossRef

40.

Mathieu J, Allard P, Gobeil G, Girard M, De Braekeleer M, Begin P (1997) Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 49:1646–1650PubMedCrossRef

41.

Veyckemans F, Scholtes JL (2013) Myotonic Dystrophies type 1 and 2: anesthetic care. Paediatr Anaesth [Epub ahead of print]

42.

Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, Pourmand R, Otten RF, Bhakta D, Nair GV, Marashdeh MM, Zipes DP, Pascuzzi RM (2008) Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 358:2688–2697PubMedCrossRef

43.

Groh WJ, Bhakta D (2012) Arrhythmia management in myotonic dystrophy type 1. JAMA 308:337–338PubMed

44.

Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, Bandera F, De Ambroggi L, Meola G (2012) The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): Long-term outcomes. Int J Cardiol [Epub ahead of print]

45.

Wahbi K, Meune C, Porcher R, Becane HM, Lazarus A, Laforet P, Stojkovic T, Behin A, Radvanyi-Hoffmann H, Eymard B, Duboc D (2012) Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 307:1292–1301PubMedCrossRef

46.

Das M, Moxley RT III, Hilbert JE, Martens WB, Letren L, Greene MH, Gadalla SM (2012) Correlates of tumor development in patients with myotonic dystrophy. J Neurol 259:2161–2166PubMedCrossRef

47.

Gadalla SM, Lund M, Pfeiffer RM, Gortz S, Mueller CM, Moxley RT III, Kristinsson SY, Bjorkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH (2011) Cancer risk among patients with myotonic muscular dystrophy. JAMA 306:2480–2486PubMedCrossRef

48.

Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT III, Greene MH (2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 20:2009–2020PubMedCrossRef

49.

Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM (2012) Increased cancer risks in myotonic dystrophy. Mayo Clin Proc 87:130–135PubMedCrossRef

50.

Meola G (2010) Myotonic dystrophies as a brain disorder. Neurol Sci 31:863–864PubMedCrossRef

Titel: Diagnostic odyssey of patients with myotonic dystrophy
verfasst von: James E. Hilbert
Tetsuo Ashizawa
John W. Day
Elizabeth A. Luebbe
William B. Martens
Michael P. McDermott
Rabi Tawil
Charles A. Thornton
Richard T. Moxley III
Publikationsdatum: 01.10.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 10/2013
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-6993-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2013

Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis

Brain white matter diffusion tensor metrics from clinical 1.5T MRI distinguish between ALS phenotypes

Anti-GAD antibody ocular flutter: expanding the spectrum of autoimmune ocular motor disorders

Targeted next generation sequencing in SPAST-negative hereditary spastic paraplegia

Videogame-based coordinative training can improve advanced, multisystemic early-onset ataxia